Exchange: OTC Sector: Healthcare Industry: Biotechnology
0.00% $0.0001
America/New_York / 26 apr 2024 @ 11:08
FUNDAMENTALS | |
---|---|
MarketCap: | 0.236 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | Nov 14, 2016 |
SharesOutstanding: | 2 356.27 mill |
Avg Daily Volume: | 0.0003 mill |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/15 | 4/15 | 1/16 | 2/16 | 3/16 | 4/16 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 136.10 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0002 - 0.0002 ( +/- 0.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2017-02-16 | Hausman Marvin S Md | Buy | 250 000 | Common Stock |
2017-02-14 | Hausman Marvin S Md | Buy | 300 000 | Common Stock |
2017-02-14 | Hausman Marvin S Md | Buy | 200 000 | Common Stock |
2017-02-14 | Hausman Marvin S Md | Buy | 600 000 | Common Stock |
2017-02-14 | Hausman Marvin S Md | Buy | 1 861 170 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 28 transactions |
Buy: 10 963 957 | Sell: 1 335 722 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0001 (0.00% ) |
Volume | 0.0150 mill |
Avg. Vol. | 0.0003 mill |
% of Avg. Vol | 4 504.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.